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Abstract Introduction: Multiple myeloma is a neoplastic
disorder characterized by clonal proliferation of plasma
cells. We aimed to carry out a retrospective audit to describe
clinical and laboratory features of patients newly diagnosed
with multiple myeloma.
Materials and Methods: Records of all patients initially
diagnosed with multiple myeloma at the haematology clinic
of Aga Khan University Hospital, Nairobi, from January 1,
1999 to December 31, 2011 were reviewed. Diagnosis of
multiple myeloma was based on (1) increased numbers of
abnormal, atypical or immature plasma cells in a bone mar-
row aspirate or trephine, (2) presence of monoclonal protein
or free light chains in serum or urine and (3) bone lesions
consistent with multiple myeloma.
Results: Seventy-four patients were diagnosed with multiple
myeloma. The median age at diagnosis was 59 years. Males
comprised 53%. The most common presenting complaints
were bone pain in 56 (76%), recurrent infections in 11
(16%) and fatigue in 24 (33%) patients. Anaemia (Hb <
10 g/dl) was present at diagnosis in 47% of patients while
25 (34%) presented with hypercalcaemia (serum calcium >
2.6 mmol/l) and 38 patients (52%) had renal failure at diag-
nosis (serum creatinine > 110μmol/l). A monoclonal band
was demonstrated in 56 patients (76%). Nine patients (12%)
had light chain myeloma while only 4 patients had non-
secretory myeloma. One patient was found to have biclonal
myeloma.
Conclusion: The median age of patients at diagnosis is lower
than that reported in other populations [59 years versus 66–
68 years] and may indicate a younger age of incidence of the
pre-malignant monoclonal gammopathy of undetermined
significance (MGUS) in African patients.
Keywords Multiple myeloma · Plasma cell · Monoclonal
gammopathy of undetermined significance · MGUS ·
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Résumé Introduction : Le myélome multiple est une néopla-
sie caractérisée par une prolifération clonale des plasmocytes.
Cette étude cherchait à décrire les caractéristiques cliniques et
biologiques des nouveaux cas du myélome multiple.
Méthodes : Les dossiers des patients diagnostiqués avec le
myélome multiple, du 1er janvier 1999 au 31 décembre
2011 à la clinique d’hématologie de l’Aga Khan University
Hospital de Nairobi (AKUH), furent examinés. Le diagnostic
était basé sur : 1) excès de plasmocytes anormaux, atypiques
ou immatures dans le myélogramme ou dans la biopsie ostéo-
médullaire ; 2) présence d’une protéine monoclonale ou des
chaînes légères isolées dans le sérum ou l’urine ; 3) lésions
osseuses caractéristiques du myélome multiple.
Résultats : Soixante-quatorze patients étaient diagnostiqués
avec le myélome multiple dont 53 % étaient des hommes.
L’âge médian au diagnostic était de 59 ans. Les plaintes les
plus fréquentes étaient : douleurs osseuses (56 patients,
76 %), infections récurrentes (11 patients, 16 %) et fatigue
(24 patients, 33 %). Quarante-sept pour cent des patients
avaient une anémie (hémoglobine < 10 g/dl) ; 25 patients
(35 %), une hypercalcémie (calcium sérique > 2,6 mmol/l)
et 38 patients (52 %), une insuffisance rénale (créatinine sér-
ique > 110 μmol/l). Une bande monoclonale était démontrée
chez 56 (76 %) patients. Neuf patients (12 %) avaient le
myélome multiple à chaînes légères tandis que seuls quatre
patients avaient le myélome non secrétant. Un patient avait
le myélome biclonal.
Conclusion : L’âge médian au diagnostic est moins que celui
décrit dans les autres populations (59 contre 66–68 ans).
Cela suggère que la gammopathie monoclonale prémaligne
de signification indéterminée (MGUS) est fréquente à un âge
plus jeune chez les Africains.
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Introduction
Multiple myeloma (MM) is a plasma cell neoplasm that
accounts for almost 15% of all haematological malignan-
cies [1]. It is twice as common in African Americans as in
white persons and is slightly more common in men than in
women. The median age at onset is 66 years [1].
MM evolves from a pre-malignant condition clinically
known as monoclonal gammopathy of undetermined signif-
icance (MGUS) [2]. The precise mechanisms by which
MGUS evolves into MM are unclear [3].
The most common presenting symptoms of MM are
fatigue, bone pain and recurrent infections [1]. Anaemia is
present in 70% of patients at diagnosis. Hypercalcaemia is
found in about one out of four patients. Skeletal abnormalities
can be diagnosed by conventional radiography in approxi-
mately 80% of patients while a monoclonal [M] protein can
be detected by serum protein electrophoresis in 82% of
patients. When immunofixation is included, up to 93% of
patients will demonstrate an M protein [4,5].
The International Myeloma Working Group criteria for
the diagnosis of symptomatic MM demonstrate the impor-
tance of end organ damage in addition to laboratory findings
in making the diagnosis [2]. The following three criteria
must be met:
• presence of a serum or urinary monoclonal protein;
• presence of clonal plasma cells in the bone marrow or a
plasmacytoma;
• presence of end organ damage related to the plasma cell
dyscrasia which includes: increased calcium concentra-
tion, lytic bone lesions, anaemia and renal failure.
Prognostic indicators in MM are scored more commonly
using the International Staging System [ISS] which utilizes
serum beta 2 microglobulin [B2M] and serum albumin
levels to predict disease stage and survival [6,7]. This is
shown in Table 1.
Median survival for ISS stage I is estimated at
62 months, ISS stage II at 44 months and 29-month median
survival for ISS stage III [7]. Other independent prognostic
factors include performance status, lactate dehydrogenase
levels, plasma cell labelling index and plasmablastic mor-
phology [6,8,9]. Presence of cytogenetic abnormalities,
such as deletion of chromosomes 13 and17, hypodiploidy
and demonstration of translocations t(4;14) and t(14;16),
have been proposed as potentially useful prognostic mar-
kers and future therapeutic targets [3,8]. These are all of
limited availability in Kenya as few laboratories have the
capacity for molecular testing. The cost is also prohibitive
to most of our patients.
Autologous stem cell transplant is considered the gold
standard curative option for young patients with MM. Ther-
apy for patients not eligible for stem cell transplants has
evolved from melphalan and prednisone combination
which results in partial remission in about 50% of patients.
Current therapy utilizes the novel agents – thalidomide, bor-
tezomib and lenalidomide with or without conventional che-
motherapy [10–12].
Materials and methods
Hospital records of all patients diagnosed of MM at the hae-
matology clinic of Aga Khan University Hospital (AKUH)
from January 1, 1999 to December 31, 2011 were reviewed.
Diagnosis of MM was based on findings of:
• plasmacytosis equal to or greater than 10% in a bone mar-
row specimen;
• presence of a monoclonal protein in serum or urine;
• clinical findings of anaemia, bone lesions characteristic of
myeloma, hypercalcaemia and renal impairment.
Patients with plasmacytosis due to underlying connec-
tive tissue disorders, liver disease, metastatic carcinoma or
HIV infection were excluded. Also excluded were patients
with monoclonal gammopathy of undetermined signifi-
cance (MGUS), smoldering MM, solitary plasmacytoma
and plasma cell leukemia.
Physical examination, laboratory results and radiology
findings dating to within three months of diagnosis were
reviewed and recorded. Information was obtained from
patients’ medical records.
Results
Seventy-four patients were initially diagnosed with MM
from January 1, 1999 to December 31, 2011. The patients
ranged in age from 30 to 99 years. The median age at
Table 1 International Staging System [ISS] scoring system
(page 4).
ISS stage Features
Stage I B2M < 3.5 mg/l; serum albumin ≥ 3.5 g/dl
Stage II Neither stage I nor stage II
Stage III B2M ≥ 5.5 mg/l
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diagnosis was 59 years. Thirty-one patients (53%) were
male. This is shown in Fig. 1.
Presenting complaints
The most common presenting complaints were bone pain in
56 (77%) and fatigue in 24 (33%) patients. Recurrent infec-
tions, considered a common feature of MM in other studies,
were only reported in 11 patients (17%) in this cohort. This
is depicted in Fig. 2.
Haematologic and biochemical blood findings
Anaemia, defined as haemoglobin of less than 10 g/dl, was
present in 47% of patients. Renal failure, defined by serum
creatinine greater than 110 μmol/l, was present in 52% of
patients. The patient haematologic and biochemical abnor-
malities on presentation are shown in Fig. 3.
Monoclonal proteins
A monoclonal band was demonstrated by serum protein
electrophoresis in 45 patients (78%). Nine patients (16%)
had light chain myeloma. One patient was found to have
biclonal myeloma. Four patients had non-secretory mye-
loma. The demonstration of monoclonal bands is shown in
Table 2.
The most common immunoglobulin demonstrated was
IgG kappa followed by IgA kappa. Monoclonal proteins by
type are depicted in Fig. 4.
Radiographic findings
Skeletal abnormalities were demonstrated in 57 patients
(77%). Lytic lesions were the most commonly reported
Fig. 1 Patients diagnosed with multiple myeloma defined by age
group (page 5)
Fig. 2 Patient presenting complaints at time of diagnosis (page 6)
Fig. 3 Patient haematologic and biochemical abnormalities on pre-
sentation (page 6)
Table 2 Demonstration of monoclonal bands (page 6).
Serum M protein 78%
Serum + urine M protein 87%
Light chains only 4%
Non-secretory 6%
Fig. 4 Monoclonal protein by type (page 6)
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abnormalities on skeletal survey (62%), followed by vertebral
collapse/compression (38%) and osteoporosis (36%). The
most common sites for radiographic abnormalities were the
lumbar spine (50%) and skull (11%). Figure 5 shows skeletal
lesions by proportion in patients with MM. Lytic lesions were
more common in ribs than in other sites, while compression
fractures were most common in the lumbar spine. Pathologi-
cal fractures not due to compression were reported in 15% of
patients.
Bone marrow examination
Bone marrow plasmacytosis was demonstrated via aspirates
or trephine biopsies. Plasma cell populations in our patients
ranged from 2% to >90% of haematopoietic cells.
Discussion
MM was diagnosed in 74 patients at the haematology clinic
of AKUH over a ten-year period from January 1, 1999 to
December 31, 2011.
The median age of 59 years at diagnosis is younger than
the median age of 66–68 years reported in other studies
[1,13]. Our patient population being African in origin might
have a younger age of diagnosis of MM than other ethnic
groups. This has been proposed to be due to a higher inci-
dence and younger age of development of monoclonal gam-
mopathy of undetermined significance (MGUS) in Africans
compared to other ethnic groups [14,15]. MGUS is consid-
ered a pre-malignant condition that leads to myeloma and thus
it may be deduced that a younger age of development of
MGUS leads to younger age of development of myeloma.
However, as MGUS screening is not routinely done in
Kenya, this fact is yet to be verified in our population. This
may also explain why our patients tend to present with overt
end organ damage myeloma at a younger age.
Bone pains were the most common presenting complaints
present in 76%, followed by fatigue in 33% of patients. A sig-
nificant proportion of patients (19%) presentedwith neurologic
symptoms such as paraesthesias or paraplegias. This might
suggest advanced bony lesions with collapse or compression
at the time of diagnosis, perhaps due to delayed presentation of
the patient to the haematology clinic, delayed referral to a ter-
tiary institution or delay in diagnosing myeloma.
Renal failure was demonstrated in over half of our
patients (58%). Kidney disease in myeloma is often asymp-
tomatic and most commonly results from myeloma kidney
(precipitation of monoclonal light chains in distal and col-
lecting tubules). It is of note that kidney disease in African
patients is often due to a higher prevalence of diabetes and
hypertension with concurrent nephropathy. To what extent
this affects the incidence of renal disease in myeloma was
not established in our study.
Hypercalcaemia due to lytic bone resorption was present
in 33% of our patients, less than half of those who had radio-
logic evidence of skeletal abnormalities (77%). Hypercal-
caemia is also a less described contributor of renal failure
in myeloma.
Anaemia was present in 50% of our patients, far less
than described in other studies [1]. Anaemia in myeloma
results from inadequate production of red blood cells due
to either erythropoietin deficiency from accompanying
renal failure or pronounced marrow replacement by clonal
plasma cells.
Monoclonal proteins were demonstrated by electrophore-
sis and immunofixation of serum and/or urine, and urine light
chain detection. Combinations of serum and urine assays
demonstrated M proteins in 94% of patients. Four patients
were found to have non-secretory myeloma – defined in our
study as the absence of monoclonal proteins by serum or urine
electrophoresis. The absence of free light chain assay in our
institution at the time of this study might account for these
four patients.
One patient was found to have biclonal myeloma with
both IgG kappa and IgG lambda monoclonal proteins dem-
onstrated on serum protein electrophoresis. This is a rare
finding described in less than 2% of myeloma patients.
This retrospective audit focused on clinical and biochem-
ical findings in patients with MM at diagnosis. Ours is a
hospital-based cohort from one referral centre in the country.
Prospective studies determining prognostic factors and sur-
vival rates in our patient population are lacking and we hope
that more publications from other research groups and ter-
tiary institutions in the country will follow.
Declaration This study was carried out in compliance with
the laws of Kenya concerning hospital-based retrospective
audits.
Fig. 5 Skeletal lesions by proportion in patients with multiple
myeloma (page 6)
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